UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

Journal of clinical oncology, 2003-05, Vol.21 (10), p.2004-2010

2003

Volltextzugriff (PDF)

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Journal of clinical oncology, 2005-07, Vol.23 (19), p.4390-4398

2005

Volltextzugriff (PDF)

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4820-4829

2012

Volltextzugriff (PDF)

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Critical reviews in oncology/hematology, 2001-07, Vol.39 (1), p.181-194

2001

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA

PloS one, 2011, Vol.6 (12), p.e28005

2011

Volltextzugriff (PDF)

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

European journal of nuclear medicine and molecular imaging, 2011-11, Vol.38 (11), p.2066-2076

2011

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression during tumor angiogenesis

European journal of nuclear medicine and molecular imaging, 2011-07, Vol.38 (7), p.1335-1343

2011

Volltextzugriff (PDF)

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5242-5246

2006

Volltextzugriff (PDF)

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

Investigational new drugs, 2013-06, Vol.31 (3), p.714-723

2013

Volltextzugriff (PDF)

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW

American journal of translational research, 2012, Vol.4 (3), p.333-346

2012

Volltextzugriff (PDF)

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105

European journal of nuclear medicine and molecular imaging, 2012, Vol.39 (1), p.138-148

2012

Volltextzugriff (PDF)

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW

Molecular pharmaceutics, 2012-08, Vol.9 (8), p.2339-2349

2012

Volltextzugriff (PDF)

Choosing an optimal radioimmunotherapy dose for clinical response

Cancer, 2002-02, Vol.94 (S4), p.1275-1286

2002

Volltextzugriff (PDF)

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy

International journal of radiation oncology, biology, physics, 2000-04, Vol.47 (1), p.115-119

2000

Volltextzugriff (PDF)

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy

Cancer biotherapy & radiopharmaceuticals, 2003-04, Vol.18 (2), p.253-258

2003

Volltextzugriff (PDF)

Antiproliferative Properties of Toremifene on AIDS-Related Kaposi’s Sarcoma Cells

Chemotherapy (Basel), 2002-12, Vol.48 (5), p.238-243

2002

Volltextzugriff (PDF)

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

Cancer biotherapy & radiopharmaceuticals, 2003-04, Vol.18 (2), p.165-178

2003

Volltextzugriff (PDF)

Positron Emission Tomography Imaging of CD105 Expression with a .sup.64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA

PloS one, 2011-12, Vol.6 (12)

2011

Volltextzugriff (PDF)

Modulation of angiogenic biomarkers in patients receiving high-dose TRC105

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e21038-e21038

2012

Volltextzugriff (PDF)

Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation

Radiation research, 1995-04, Vol.142 (1), p.12

1995

Volltextzugriff (PDF)

Radioimmunotherapy of non-Hodgkin’s lymphoma: Clinical development of the Zevalin regimen

Biotechnology Annual Review, 2004, Vol.10, p.265-295

2004

Volltextzugriff (PDF)

A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Clinical cancer research, 2012-07, Vol.18 (17), p.4820-4829

2012

Volltextzugriff (PDF)

Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3042-3042

2012

Volltextzugriff (PDF)

A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3034-3034

2012

Volltextzugriff (PDF)

Summary of the proceedings of the United States–Japan lung cancer clinical trials summit: San Francisco, CA, 20–22 November, 1998

Lung cancer (Amsterdam, Netherlands), 1999-06, Vol.24 (3), p.181-191

1999

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(127)
Tagungsberichte
(2)

Sprache

Englisch
(129)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

Positron emission tomography imaging of CD105 expression during tumor angiogenesis

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW

Choosing an optimal radioimmunotherapy dose for clinical response

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy

Antiproliferative Properties of Toremifene on AIDS-Related Kaposi’s Sarcoma Cells

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

Positron Emission Tomography Imaging of CD105 Expression with a .sup.64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA

Modulation of angiogenic biomarkers in patients receiving high-dose TRC105

Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation

Radioimmunotherapy of non-Hodgkin’s lymphoma: Clinical development of the Zevalin regimen

A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients

A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors

Summary of the proceedings of the United States–Japan lung cancer clinical trials summit: San Francisco, CA, 20–22 November, 1998

Suchergebnisse filtern